JP2022507103A5 - - Google Patents

Info

Publication number
JP2022507103A5
JP2022507103A5 JP2021525303A JP2021525303A JP2022507103A5 JP 2022507103 A5 JP2022507103 A5 JP 2022507103A5 JP 2021525303 A JP2021525303 A JP 2021525303A JP 2021525303 A JP2021525303 A JP 2021525303A JP 2022507103 A5 JP2022507103 A5 JP 2022507103A5
Authority
JP
Japan
Prior art keywords
corticosteroid
dose
hsd1 inhibitor
urinary
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021525303A
Other languages
English (en)
Japanese (ja)
Other versions
JP7472122B2 (ja
JP2022507103A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046449 external-priority patent/WO2020106337A1/en
Publication of JP2022507103A publication Critical patent/JP2022507103A/ja
Publication of JP2022507103A5 publication Critical patent/JP2022507103A5/ja
Priority to JP2024063590A priority Critical patent/JP2024098991A/ja
Application granted granted Critical
Publication of JP7472122B2 publication Critical patent/JP7472122B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021525303A 2018-11-20 2019-08-14 コルチコステロイドを投与する方法 Active JP7472122B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024063590A JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769932P 2018-11-20 2018-11-20
US62/769,932 2018-11-20
PCT/US2019/046449 WO2020106337A1 (en) 2018-11-20 2019-08-14 Methods for administering corticosteroids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024063590A Division JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Publications (3)

Publication Number Publication Date
JP2022507103A JP2022507103A (ja) 2022-01-18
JP2022507103A5 true JP2022507103A5 (enExample) 2022-08-23
JP7472122B2 JP7472122B2 (ja) 2024-04-22

Family

ID=70774135

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525303A Active JP7472122B2 (ja) 2018-11-20 2019-08-14 コルチコステロイドを投与する方法
JP2024063590A Pending JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024063590A Pending JP2024098991A (ja) 2018-11-20 2024-04-10 コルチコステロイドを投与する方法

Country Status (10)

Country Link
US (2) US12220412B2 (enExample)
EP (1) EP3883578A4 (enExample)
JP (2) JP7472122B2 (enExample)
CN (1) CN113329754A (enExample)
AU (2) AU2019384074B2 (enExample)
BR (1) BR112021009653A2 (enExample)
CA (1) CA3120339A1 (enExample)
IL (2) IL319327A (enExample)
MX (2) MX2021005801A (enExample)
WO (1) WO2020106337A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022076398A1 (en) * 2020-10-07 2022-04-14 Surface Ophthalmics, Inc. Pharmaceutical kits and their use for treating dry eye disease
CN113329754A (zh) 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
CN113473970A (zh) 2018-12-27 2021-10-01 瑟菲斯眼科股份有限公司 用以治疗眼表疾病的眼科药物组合物和方法
WO2020161317A1 (en) * 2019-02-08 2020-08-13 Sanofi Biotechnological optimization of microorganisms for the 1,2-dehydrogenation of steroids
WO2022240598A1 (en) 2021-05-10 2022-11-17 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
AU2023273030A1 (en) 2022-05-16 2024-11-07 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
WO2023225507A1 (en) * 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
AU2024348222A1 (en) * 2023-09-27 2026-04-16 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid-mediated diseases
GB202408335D0 (en) 2024-06-11 2024-07-24 Astrazeneca Ab Therapies for wound treatment

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907821A (en) 1974-11-20 1975-09-23 Upjohn Co 2-{8 3-{8 1-(DIMETHYLAMINO)CYCLOPROPYL{8 -4H-1,2,4-triazol-4-yl{8 {0 benzophenone
US4577020A (en) 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
IL84093A (en) 1986-10-09 1992-09-06 Ciba Geigy Ag Aralkyl-4h-1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them
GB0101447D0 (en) * 2001-01-19 2001-03-07 Univ Edinburgh Regulation of glucocorticoid concentration
GB0107383D0 (en) * 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
AUPR878201A0 (en) 2001-11-09 2001-12-06 Fujisawa Pharmaceutical Co., Ltd. New compounds
AU2002361861A1 (en) 2001-12-21 2003-07-30 Rhode Island Hospital SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
AU2003207717B9 (en) 2002-02-01 2009-05-07 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
AR040847A1 (es) 2002-08-09 2005-04-20 Astrazeneca Ab 1,2,4-oxadiazoles como moduladores de receptores de glutamato metabotropicos, para el tratamiento de desordenes neurologicos y psiquiatricos
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
JP2006522747A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 縮合１，２，４−トリアゾールの薬学的使用
ATE482747T1 (de) 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
US20060094699A1 (en) * 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
WO2004106294A2 (en) 2003-05-29 2004-12-09 Merck & Co., Inc. Triazole derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase-1
EP1680114A4 (en) 2003-10-28 2008-09-24 Amgen Inc TRIAZOL COMPOUNDS AND RELEVANT PROCEDURES
JP2005170939A (ja) 2003-11-20 2005-06-30 Takeda Chem Ind Ltd 糖尿病の予防・治療剤
BRPI0417687A (pt) 2003-12-19 2007-04-03 Pfizer derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
BRPI0417947A (pt) 2003-12-22 2007-04-17 Lilly Co Eli composto, composição farmacêutica, fabricação de um medicamento para o uso no tratamento e/ou prevenção de um metabólico distúrbio, e, formulação farmacêutica
CA2560314A1 (en) 2004-03-29 2005-10-20 Merck & Co., Inc. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US7880001B2 (en) * 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US8415354B2 (en) * 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
RU2383536C2 (ru) 2004-08-04 2010-03-10 Тайсо Фармасьютикал Ко., Лтд. Производное триазола
JP4882748B2 (ja) 2004-09-16 2012-02-22 アステラス製薬株式会社 トリアゾール誘導体またはその塩
US20090093463A1 (en) 2004-11-02 2009-04-09 Agouron Pharmaceuticals Inc. Novel compounds of substituted and unsubtituted adamantyl amides
WO2006068199A1 (ja) 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な３－オキシ－１，２，４－トリアゾール誘導体
WO2006080533A1 (ja) 2005-01-31 2006-08-03 Mochida Pharmaceutical Co., Ltd. ３－アミノ－１,２,４－トリアゾール誘導体
WO2006134481A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
CN101198605A (zh) 2005-06-16 2008-06-11 辉瑞大药厂 N-(吡啶-2-基)-磺酰胺衍生物
EA200702498A1 (ru) 2005-06-16 2008-06-30 Пфайзер Инк. N-(пиридин-2-ил)сульфонамидные производные
WO2007007688A1 (ja) 2005-07-08 2007-01-18 Mochida Pharmaceutical Co., Ltd. ３,５－ジアミノ－１,２,４－トリアゾール誘導体
CA2620179C (en) 2005-08-16 2013-10-29 Icagen, Inc. Inhibitors of voltage-gated sodium channels
AR058807A1 (es) 2005-09-29 2008-02-27 Astrazeneca Ab 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
ZA200807451B (en) 2006-03-16 2010-01-27 Astellas Pharma Inc A triazole derivative or salt thereof
US20070224298A1 (en) 2006-03-23 2007-09-27 Talbott Shawn M Inhibiting 11(beta)-hsd1 with citrus flavonoids
US7435833B2 (en) 2006-04-07 2008-10-14 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
CN102076671B (zh) 2008-07-03 2013-05-15 安斯泰来制药有限公司 三唑衍生物或其盐
EP2243494A1 (en) * 2009-04-22 2010-10-27 OntoChem GmbH Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist.
WO2011068927A2 (en) * 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
UA112418C2 (uk) 2010-09-07 2016-09-12 Астеллас Фарма Інк. Терапевтичний болезаспокійливий засіб
BR112014018717A8 (pt) * 2012-03-13 2017-07-11 Abbvie Inc Método para selecionar ou identificar um sujeito para terapia de antagonista de v1b
EP3166610B1 (en) * 2014-07-09 2022-11-02 Eip Pharma, LLC Methods for treating neurologic disorders
US10894054B2 (en) 2015-04-07 2021-01-19 Intercept Pharmaceuticals, Inc. FXR agonist compositions for combination therapy
US10648506B2 (en) 2016-07-07 2020-05-12 Raul Mendoza Walking rig creeper interface
WO2018117063A1 (ja) 2016-12-20 2018-06-28 アステラス製薬株式会社 焦燥性興奮治療剤
CN113329754A (zh) 2018-11-20 2021-08-31 麻雀制药股份有限公司 用于施用皮质类固醇的方法
EP3821892A1 (en) 2019-11-12 2021-05-19 University of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds
EP3878446A1 (en) 2020-03-09 2021-09-15 Universite De Geneve Hsd11b1 inhibitors for use in immunotherapy and uses thereof
WO2023225507A1 (en) 2022-05-16 2023-11-23 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess
AU2023273030A1 (en) 2022-05-16 2024-11-07 Sparrow Pharmaceuticals, Inc. Methods and compositions for treating glucocorticoid excess

Similar Documents

Publication Publication Date Title
US20250205227A1 (en) Methods for administering corticosteroids
JP5913136B2 (ja) 糖質コルチコイド感作物質としてのプロゲストーゲンの使用方法
Hilderson et al. Treatment of renal sarcoidosis: is there a guideline? Overview of the different treatment options
Seo Perioperative glucocorticoid management based on current evidence
JP2020520889A5 (enExample)
JP2013518908A5 (enExample)
MXPA04003266A (es) Combinaciones para el tratamiento de desodrdenes inmuno-inflamatorios.
WO2008087437A1 (en) Treatment of corticoid-resistant asthma or copd with p38 map kinase inhibit (eg. sb2035809)
US20120245552A1 (en) Combination Therapy
JP2023542345A5 (enExample)
RU2021113995A (ru) Способы введения кортикостероидов
US20120309722A1 (en) Therapeutic regimens for the treatment of immunoinflammatory disorders
US11571412B2 (en) Thromboxane receptor antagonists in AERD/asthma
Babaoğlu et al. Therapeutic mechanisms of glucocorticoids, their administration and chronotherapy
JP2025509955A5 (enExample)
Papi et al. Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage
Bissell et al. Glucocorticoids
TW201726145A (zh) 用於維持皮質類固醇滑液濃度之皮質類固醇調配物
Deepalakshmi et al. A Comprehensive Review on Corticosteroids
Anandabaskar Adrenocorticosteroids and Their Antagonists
US3231468A (en) Dexamethasone-cyproheptadine oral antiflammatory compositions
US20070259841A1 (en) Combinations for the treatment of rheumatoid arthritis
Call Treatment of Adrenocorticosteroid Disorders
Fluticasone 21 CH2OH CH2OH CH2OH
Usta-Makkaoui et al. Hydrocortisone improves somnolence without hypotension in the postpartum period